Mesa Laboratories Q2 revenue rises on divisional performance
Overview
Life sciences tools maker's fiscal Q2 revenue rose 2.6% yr/yr
EPS for fiscal Q2 was $0.75, net income climbed 75% yr/yr
Company authorized new $40 mln share repurchase program
Outlook
Mesa Labs sees FY27 revenues of $250 mln to $255 mln
Company expects FY27 adjusted EBITDA of $66 mln to $68 mln
Company expects Q3 revenues to be flat year-over-year, mainly due to lower Clinical Genomics
Result Drivers
DIVISIONAL PERFORMANCE - Revenue growth was led by Sterilization and Disinfection Control and Calibration Solutions, while Biopharmaceutical Development declined
PRODUCTION RECOVERY - Resolved production issues in Sterilization and Disinfection Control led to higher shipments and revenue growth
EXPORT-CONTROL DELAYS - Biopharmaceutical Development revenues fell due to export-control processing delays impacting peptide hardware sales
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Slight Beat* | $62.34 mln | $62.20 mln (2 Analysts) |
Q2 EPS | $0.75 | ||
Q2 Net Income | $4.34 mln | ||
Q2 Basic EPS | $0.77 | ||
Q2 Gross Profit | $39.88 mln | ||
Q2 Operating Expenses | $31.49 mln | ||
Q2 Operating Income | $8.39 mln |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Mesa Laboratories, Inc. is $125.00, about 2.5% below its November 6 closing price of $128.25
The stock recently traded at 52 times the next 12-month earnings vs. a P/E of 62 three months ago
Reuters Recommended Reads
Nov 9 - Quanterix Q3 revenue rises 6.3% sequentially
Nov 9 - OraSure Technologies Q3 revenue rises, gross margin improves
Nov 9 - Hyperfine Q3 revenue jumps on higher system sales; net loss narrows
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)